Atomwise

Atomwise, Inc. was founded in 2012 and is headquartered in San Francisco, California. It is a supplier specializing in developing artificial intelligence solutions for drug discovery. The company was formerly known as Chematria and was renamed Atomwise in 2015. Atomwise's AtomNet is the first deep learning neural network used for structure-based drug design and discovery. Its speed and accuracy make it the most advanced technology for small molecule binding affinity prediction. Atomwise has enriched its AtomNet® technology with experimental data and conducted the largest molecular screening in human history—today, the molecular library used for virtual screening encompasses more than 16 billion compound molecules. Through continuous use of AtomNet® in research scenarios, Atomwise has gained valuable experimental data, covering a broader range of drug targets, homology modeling methods, protein types, and disease areas than any other AI platform.